Behind-The-Counter Guidance Stalled, But Interest Grows To Expand Access
This article was originally published in The Tan Sheet
Executive Summary
FDA executives say behind-the-counter status for nonprescription drugs resonates in discussions at the agency, but a former deputy commissioner says the agency's BTC interests are stifled by not having explicit authority
You may also be interested in...
OTC Monograph Woes No Surprise To FDA Commissioner Nominee Gottlieb
Gottlieb was asked only one question about OTC drug regulation during his confirmation hearing before the Senate HELP Committee, but it covered a large part of FDA's current concerns about the OTC market.
OTC Monograph Woes No Surprise To FDA Commissioner Nominee Gottlieb
Gottlieb was asked only one question about OTC drug regulation during his confirmation hearing before the Senate HELP Committee, but it covered a large part of FDA's current concerns about the OTC market.
Market Exclusivity Needed For Special Condition Switches – Expert
Without market exclusivity and a requirement to make generics also subject to consumer access restrictions, drug firms likely will not invest in novel switches, says a switch process veteran and Merck Consumer Care executive.